Healthcare stocks are moderately higher, with the NYSE
Healthcare Sector Index climbing about 0.2% while shares of
healthcare companies in the S&P 500 are up 0.3% as a group.
In company news, ArQule (
) is down more than 10% at $2.51 a share after saying it has
received a letter from the committee monitoring the Phase III trial
of its tivantinib drug candidate. The committee recommended
reducing dosages of the prospective liver-cancer treatment because
of a higher incidence of reduced white blood cell counts than in
ARQL is developing the drug with Daiichi Sankyo. It said the
Data Monitoring Committee recommended the study dosage be reduced
to 120 milligrams from 240 milligrams twice daily. It also said the
companies should revise its patient monitoring procedures to
confirm the safety of the lower dose.
The companies expect that the lower dosages will reduce the
incidence of neutropenia observed to date.
In other sector news,
(+) HALO, (+1.3%) Authorized to market a subcutaneous
formulation of Herceptin using its recombinant human hyaluronidase
to treat HER2-positive breast cancer inside the European Union.
(-) CYTK, (-24.9%) First presentation of data from Phase II
clinical study of omecamtiv mecarbil did not meet primary goal of
alleviating shortness of breath in patients.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.